Results 201 to 210 of about 21,302 (228)

To DOAC or Not to DOAC for Left Ventricular Thrombi—What Is the Dose?

JAMA Cardiology, 2021
Arun, Manmadhan, Jeffrey S, Berger, Tania, Ahuja   +2 more
openaire   +2 more sources

[Towards 'the best DOAC'?]

Nederlands tijdschrift voor geneeskunde, 2020
Direct oral anticoagulants (DOACs) are increasingly being prescribed for stroke prevention in patients with atrial fibrillation or for treating venous thromboembolism. In this short overview, we provide some guidance on possible differences between available DOACs as well as a comparison with traditional treatments using vitamin K antagonists.
Sander, van Doorn, Frans H, Rutten, G J, Geersing   +2 more
openaire   +1 more source

Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa.

Thrombosis Research, 2019
INTRODUCTION Lupus anticoagulant (LA) investigation in patients on anticoagulant therapy is problematic. Rivaroxaban in particular causes significant interference, prolonging both LA screening and confirmation tests, and falsely raising LA screen/confirm
E. Favaloro, G. Gilmore, Sandya Arunachalam, S. Mohammed, R. Baker   +4 more
semanticscholar   +1 more source

To DOAC or Not to DOAC for Left Ventricular Thrombi—What Is the Dose?—Reply

JAMA Cardiology, 2021
Austin A, Robinson, Cory R, Trankle, Grayson, Eubanks   +2 more
openaire   +2 more sources

DOAC dose adjustment in renal impairment

Drug and Therapeutics Bulletin, 2020
Abstract Review of: Inohara T, Holmes DN, Pieper K, et al. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart 2020;106:358–364.
openaire   +2 more sources

Heparins – DOACS – VKA

Phlebologie, 2015
SummaryPatients with cancer are at increased risk of venous thromboembolism (VTE). At the same time they have often an underlying bleeding risk. That can often make decisions surrounding the administration of anticoagulants complicate. Individual risk-benefit calculation is necessary.
openaire   +1 more source

Drug–Drug Interaction with DOACs

2021
Despite the relative recent approval, dabigatran, rivaroxaban, apixaban, and edoxaban are spreading in current clinical use, being indicated both for thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and prevention of venous thromboembolism (VTE).
Alberto Corsini, Nicola Ferri
openaire   +1 more source

An update on the bleeding risks associated with DOACs

Drug and Therapeutics Bulletin, 2017
The direct oral anticoagulants (DOACs), also referred to as novel (or non-vitamin K antagonist) oral anticoagulants (NOACs), represent a major development in anticoagulation therapy due to their rapid onset of action, predictable dose–response with fixed doses and limited interactions with food and drugs.1,2 However, these agents have been in ...
openaire   +2 more sources

[New direct oral oral anticoagulants (DOACs) - indications of DOACs].

Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2014
The direct oral anticoagulants (DOACs) were developed because of the urgent therapeutic need due to the deficits of vitamin K antagonist therapy. The predominant indications in internal medicine are the acute treatment and secondary prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) as well as stroke prevention in patients with ...
openaire   +1 more source

Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants

Clinical Chemistry and Laboratory Medicine, 2019
Background The aim of the study was to investigate the specificity of an activated charcoal-based product (DOAC Stop™) initially intended for the specific extraction of direct oral anticoagulants (DOACs) from test plasmas on a range of other ...
T. Exner, M. Ahuja, Lisa Ellwood
semanticscholar   +1 more source